Skip to main content
. 2018 Dec 10;38(2):e99876. doi: 10.15252/embj.201899876

Figure 8. CCB02 treatment prevents invasive behavior of NSCLC in 3D organotypic spheroids.

Figure 8

  1. Real‐time live imaging of NSCLC (H1975T790M) 3D spheroids with vehicle, 5 μM erlotinib, or 5 μM CCB02. At the end of live imaging, spheroids were fixed and stained for F‐actin (green). Arrow indicates invasive (vehicle‐treated) and non‐invasive (CCB02‐treated) structures in spheroids. Scale bar, 100 μm.
  2. Time series plot shows the spheroid growth rate measurements. CCB02 treatment prevents the spheroid growth rate by inhibiting the formation of invasive protrusions. More NSCLC spheroid experiments are given in Fig EV5A and B, and Movies EV5 and EV6. (N) = 3. At least 10 spheroids were measured for each condition. Error bars, mean ± SEM. Unpaired t‐test ***P < 0.0001.
  3. Experimental scheme of mouse xenograft using H1975T790M.
  4. Anti‐tumor activity of CCB02 in vivo. Left: Subcutaneous xenograft tumor volume measurements of H1975T790M (30 mg/kg of weight, daily) in nude mice treated with vehicle or CCB02. Right: Bar graph shows total tumor volume at day 1 and day 24 of vehicle‐ or CCB02‐treated xenograft. Error bars, mean ± SD with n = 8 for control vehicle and n = 8 for CCB02 treatment. Unpaired t‐test *P < 0.01.